F2G
- Company typePrivate
- Founded1998
- HeadquartersManchester, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
F2G firmographics
Firmographics- Name
- F2G
- Legal name
- F2G Ltd
- Website
- https://f2g.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
F2G industry classification
Industry- Product category
- Antifungal Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where F2G is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
F2G business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical product sales (pre-revenue): F2G is a pre-revenue biopharma company. The company is developing olorofim for the treatment of invasive aspergillosis and coccidioidomycosis, with late-stage clinical development underway. Revenue will be generated through product sales following regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
F2G product offering
Product offeringCore offering
F2G discovers and develops novel antifungal therapeutics, with its lead candidate olorofim being the first member of the orotomide class — small molecules that selectively inhibit fungal dihydroorotate dehydrogenase (DHODH) to treat invasive aspergillosis, coccidioidomycosis, and rare resistant mold infections. The company is developing olorofim in oral (Phase 3), IV, inhaled, and pediatric formulations targeting immunocompromised patients who have failed standard azole therapy. F2G is a pre-revenue late-stage biotech preparing regulatory submissions following positive Phase 3 OASIS trial results in June 2026.
Product overview
F2G is a biopharmaceutical company developing a focused portfolio of novel antifungal therapeutics centered on its lead candidate olorofim. The company has pioneered the orotomides class of antifungal agents that work through a novel dihydroorotate dehydrogenase (DHODH) inhibition mechanism. The core offering consists of olorofim available in multiple formulations: oral tablets for adult patients (Phase 3), IV formulation, inhaled formulation, and pediatric oral formulation. F2G operates a partnership with Shionogi for commercialization rights in certain regions and is preparing for regulatory submissions following positive Phase 3 OASIS trial results.
Differentiator
Problem solved
Functional benefit
Products and services
- Olorofim (oral antifungal)
- Olorofim IV Formulation
- Olorofim Inhaled Formulation
- Olorofim Pediatric Oral Formulation
- Early Access Program (compassionate use) for olorofim
Quantifiable outcome
- Phase 3 OASIS trial: All-cause mortality at Day 42 was 23.8% for olorofim vs 24.3% for AmBisome (non-inferiority demonstrated).
- +2 more outcomes
Companies that use F2G
Customer profileSegments1 record
Ideal customer profiles1 record
F2G technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
F2G partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Shionogi & Co., Ltd.coreShionogi entered a collaboration with F2G for the development and commercialization of olorofim, a novel antifungal agent, with potential deal value of up to $480 million including upfront and milestone payments. F2G and Shionogi jointly conducted the global Phase 3 OASIS trial. Following positive Phase 3 results in June 2026, Shionogi plans regulatory submissions in Europe and Asia, while F2G plans submission in the US.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
F2G competitors and assessment
Company assessmentDirect peers
- Scynexis: Scynexis developed ibrexafungerp (Brexafemme), a novel antifungal approved for vulvovaginal candidiasis and in development for invasive fungal infections. It is a direct peer as another late-stage antifungal biotech developing first-in-class mechanisms for serious and resistant fungal infections.
- Cidara Therapeutics: Cidara developed rezafungin (Rezzayo), an echinocandin antifungal approved for invasive candidiasis. It is a direct peer as an antifungal-focused biotech developing novel agents for invasive fungal infections in hospital settings.
- Amplyx Pharmaceuticals (Pfizer): Amplyx developed fosmanogepix, a novel antifungal for invasive fungal infections including aspergillosis, and was acquired by Pfizer in 2021. It is a direct peer as a developer of a first-in-class antifungal targeting DHODH-adjacent pathways for resistant mold infections.
- Basilea Pharmaceutica: Basilea developed isavuconazole (Cresemba) for invasive aspergillosis and mucormycosis and has a pipeline of antifungal agents. It is a direct peer as an antifungal-focused company competing in invasive mold infection treatment.
- Melinta Therapeutics: Melinta is a specialty anti-infectives company with antifungal and antibiotic offerings targeting serious infections. It is a direct peer as a focused anti-infectives company developing and commercializing therapies for hospital-treated infections.
Broad incumbents
- Pfizer: Pfizer markets AmBisome (the comparator in F2G's Phase 3 trial) and voriconazole, and acquired Amplyx's fosmanogepix program. As the incumbent in invasive aspergillosis therapy, Pfizer is the broad competitor olorofim will displace or compete against in hospital formularies.
- Merck & Co. Merck has historical antifungal franchises and infectious disease expertise. It is a broad incumbent in the antifungal and broader anti-infectives space against which olorofim will compete for hospital share and prescriber attention.
- Astellas Pharma: Astellas markets Cresemba (isavuconazole) outside the US for invasive aspergillosis through partnership and has a broader antifungal presence via historical venture investments. It is a broad incumbent overlapping with olorofim's target indications.
Others
- Shionogi & Co. Shionogi is F2G's $480M commercialization partner for olorofim in Europe and Asia. As a partner with shared economics and strategic interest in antifungal success, Shionogi is the most directly economically-linked company and a related player rather than a direct competitor.
- T2 Biosystems: T2 Biosystems develops diagnostic panels for invasive fungal infections and bloodstream infections. It is an adjacent player enabling earlier detection of the same patient population F2G targets with olorofim, making it thematically related but not a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
F2G social profiles
Digital presenceF2G compliance and trust
Trust signalCompliance2 records
F2G financial estimates
Financial estimateRevenue estimate
Valuation estimate
F2G leadership team
Management profileNumber of profiles
Profiles23 records
F2G subsidiaries and ownership
Company hierarchySubsidiaries2 records
F2G funding detail
Funding detailFunding overview
Funding rounds13 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
F2G M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about F2G
What does F2G do?
F2G discovers and develops novel antifungal therapeutics, with its lead candidate olorofim being the first member of the orotomide class — small molecules that selectively inhibit fungal dihydroorotate dehydrogenase (DHODH) to treat invasive aspergillosis, coccidioidomycosis, and rare resistant mold infections. The company is developing olorofim in oral (Phase 3), IV, inhaled, and pediatric formulations targeting immunocompromised patients who have failed standard azole therapy. F2G is a pre-revenue late-stage biotech preparing regulatory submissions following positive Phase 3 OASIS trial results in June 2026.
Is F2G a public or private company?
F2G is a private company. It is classified as venture growth investor backed and is currently operating.
When was F2G founded?
F2G was founded in 1998. It employs 51 to 100 people.
Where is F2G based?
F2G is headquartered in Manchester, United Kingdom, in the Europe region.
How does F2G make money?
One revenue line is on record: pharmaceutical product sales (pre-revenue).
Who are F2G's main competitors?
Direct peers on record are Scynexis, Cidara Therapeutics, Amplyx Pharmaceuticals (Pfizer), Basilea Pharmaceutica and Melinta Therapeutics. Broad incumbents are Pfizer, Merck & Co. and Astellas Pharma. Others are Shionogi & Co. and T2 Biosystems.
Does F2G have an API?
No public API is recorded for F2G.
What industry is F2G in?
F2G's product category is Antifungal Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.